BCG for Therapeutic Use

DRUG4 trials

Sponsors

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Chengdu CoenBiotech Co., Ltd

Conditions

BCGNon-Muscle Invasive Bladder CancerNon-muscular Invasive Bladder Cancer

Phase 1

BCG for Therapeutic Use Phase I Clinical Trial

CompletedNCT06100653

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Non-muscular Invasive Bladder Cancer

Start: 2023-11-22End: 2025-04-30Updated: 2025-05-31

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

CompletedNCT06350838

Chengdu CoenBiotech Co., LtdNon-muscular Invasive Bladder Cancer

Start: 2022-11-11End: 2023-02-13Updated: 2024-04-05

Phase 3

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

RecruitingNCT06241755

Chengdu CoenBiotech Co., LtdNon-Muscle Invasive Bladder Cancer

Start: 2023-12-28End: 2026-09-03Target: 412Updated: 2024-02-05

BCG for Therapeutic Use Phase Ⅲ Clinical Trial

Active, not recruitingNCT06747455

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.BCG

Start: 2025-04-08End: 2028-12-31Updated: 2026-04-27